State of the small intestinal microbiome in adolescents with constitutional-exogenous obesity and lipid metabolism disorders

Introduction. The intestinal microbiome has attracted much attention from scientists worldwide due to its complex interaction with many diseases, including obesity, metabolic disorders, and cardiovascular diseases. Objective: to study the state of the small intestinal microbiome in adolescents with constitutional-exogenous obesity and lipid metabolism disorders. Materials and methods. A one-time case-control study was conducted on 50 adolescents aged 12-17 years with constitutional-exogenous obesity of grades 2-4 living in St. Petersburg. Complaints, life history data and disease, objective clinical examination, and laboratory and instrumental research results were assessed. In particular, special attention was paid to the analysis of the lipidogram. The state of the parietal microbiota of the small intestine was studied by the method of blood gas chromatography-mass spectrometry (MSMM) (according to the author’s method of Osipov G.A.). Statistical data processing was carried out using the IBM SPSS Statistics 27.0 program (USA). Results and discussion. Analysis of the quantitative composition of the small intestine microbiome showed that there was a redistribution of phylotypes. It was characterized by a general decrease in the number of all identified bacteria and the predominance of Firmicutes microorganisms. Moreover, with hypercholesterolemia, an increase in clostridium propionicum, lactobacillus spp and lactococcus spp was noted, and with hypertriglyceridemia, a decrease in micromycete spp (sitosterol). Our data were comparable with the results of work conducted by scientists from China. However, a number of foreign studies have shown that lactobacilli contribute to a decrease in the level of total cholesterol, LDL. This problem requires further study. Conclusion. In adolescents with obesity and dyslipidemia, the microbiome of the small intestine was found to have a decreased diversity and a predominance of Firmicutes microorganisms, a decreased amount of micromycete spp (sitosterol).

obesity, intestinal microbiota, dyslipidemia, Firmicutes, lactobacillus

1. Novikova V.P., Gurova M.M. Multidisciplinary problems of obesity in children. St. Petersburg. SpecLit, 2018, 582 p. (In Russ.)@@ Мультидисциплинарные проблемы ожирения у детей / под ред. В.П. Новиковой, М.М. Гуровой - Санкт-Петербург: СпецЛит, 2018. - 582 с.

2. Balukova E.V., Baryshnikova N.V., Bogdanova N.M. et al.Intestinal microbiota as a regulator of human organs and systems: A guide for doctors. Moscow: GEOTAR-Media, 2024. 344 p. (In Russ.) doi: 10.33029/9704-8174-5-IMR-2024-1-344.@@ Кишечная микробиота как регулятор работы органов и систем человека: Руководство для врачей / Е.В. Балукова, Н.В. Барышникова, Н.М. Богданова и др. - Москва: ГЭОТАР-Медиа, 2024. - 344 с. doi: 10.33029/9704-8174-5-IMR-2024-1-344.

3. Kharitonova L. A., Papysheva O.V., Mayatskaya T.A., Kotaysh G.A. State of intestinal microbiota in dyslipidemia in children. Experimental and Clinical Gastroenterology. 2019;171(11): 76-82. (In Russ.) doi: 10.31146/1682-8658-ecg-171-11-76-827.@@ Харитонова Л.А., Папышева О.В., Маяцкая Т.А., Котайш Г.А. Состояние микробиоты кишечника при дислипидемии у детей. Экспериментальная и клиническая гастроэнтерология. 2019;171(11): 76-82. doi: 10.31146/1682-8658-ecg-171-11-76-82.

4. Skvortsova O.V., Migacheva N.B., Lyamin A.V., Mikhailova E.G., Kayumov K.A., Alekseev D.V. Features of the composition of intestinal microbiota in children with obesity depending on the presence or absence of metabolic complications. Medical Council. 2024;(19):245-253. (In Russ.) doi: 10.21518/ms2024-371.@@ Скворцова О.В., Мигачева Н.Б., Лямин А.В., Михайлова Е.Г., Каюмов К.А., Алексеев Д.В. Особенности состава кишечной микробиоты у детей с ожирением в зависимости от наличия или отсутствия метаболических осложнений. Медицинский Совет. 2024;(19):245-253. doi: 10.21518/ms2024-371.

5. Shabalov A.M., Kornienko E.A., Arsentiev V.G. et al. Relationship between small intestinal bacterial overgrowth syndrome and lipid metabolism in children and adolescents with obesity of varying severity. Effective Pharmacotherapy. 2025; 21 (18): 6-11. (In Russ.) doi: 10.33978/2307-3586-2025-21-18-6-11.@@ Шабалов А.М., Корниенко Е.А., Арсентьев В.Г. и др. Взаимосвязь синдрома избыточного бактериального роста в тонкой кишке и липидного обмена у детей и подростков с ожирением различной степени тяжести. Эффективная фармакотерапия. 2025; 21 (18): 6-11. doi: 10.33978/2307-3586-2025-21-18-6-11.

6. Evdokimova N.V., Shogiradze L.D., Pokhlebkina A.A. et al. Small intestinal microbiota in adolescent girls suffering from obesity. Experimental and Clinical Gastroenterology. 2023; 7(215): 34-41. (In Russ.) doi: 10.31146/1682-8658-ecg-215-7-34-41.@@ Евдокимова Н.В., Шогирадзе Л.Д., Похлебкина А.А. и др. Микробиота тонкой кишки у девочек-подростков, страдающих ожирением. Экспериментальная и клиническая гастроэнтерология. 2023; 7(215): 34-41. doi: 10.31146/1682-8658-ecg-215-7-34-41.

7. Bolotova N.V., Cherednikova K.A., Filina N. Yu. et al. Features of the metabolic activity of intestinal microbiota in children with obesity. Experimental and Clinical Gastroenterology. 2024; 1(221): 13-20. (In Russ.) doi: 10.31146/1682-8658-ecg-221-1-13-20.@@ Болотова Н.В., Чередникова К.А., Филина Н.Ю. и др. Особенности метаболической активности кишечной микробиоты у детей с ожирением. Экспериментальная и клиническая гастроэнтерология. 2024; 1(221): 13-20. doi: 10.31146/1682-8658-ecg-221-1-13-20.

8. Peterkova V.A., Bezlepkina O.B., Bolotova N.V. et al. Clinical guidelines «Obesity in children». Problems of Endocrinology. 2021;67(5):67-83. (In Russ.) doi: 10.14341/probl12802.@@ Петеркова В.А., Безлепкина О.Б., Болотова Н.В. и др. Ожирение у детей. Клинические рекомендации. Проблемы Эндокринологии. 2021;67(5):67-83. doi: 10.14341/probl12802.

9. Komissarova M. Yu., Mirnaya A.S., Evdokimova N.V., Podorova L.A.Intestinal microbiota in children with obesity: features of composition and role in pathogenesis. Questions of Dietology. 2024;14(2): 50-59. (In Russ.) doi: 10.20953/2224-5448-2024-2-50-59.@@ Комиссарова М.Ю., Мирная А.С., Евдокимова Н.В., Подорова Л.А. Микробиота кишечника у детей с ожирением: особенности состава и роль в патогенезе. Вопросы диетологии. 2024;14(2): 50-59. doi: 10.20953/2224-5448-2024-2-50-59.

10. Kalnina I., Gudra D., Silamikelis I. et al. Variations in the Relative Abundance of Gut Bacteria Correlate with Lipid Profiles in Healthy Adults. Microorganisms. 2023 Oct 28;11(11):2656. doi: 10.3390/microorganisms11112656.

11. Wu Y., Zhang Q., Ren Y., Ruan Z. Effect of probiotic Lactobacillus on lipid profile: A systematic review and meta-analysis of randomized, controlled trials. PLoS One. 2017 Jun 8;12(6): e0178868. doi: 10.1371/journal.pone.0178868.

12. Rebolledo C., Cuevas A., Zambrano T. et al. Bacterial Community Profile of the Gut Microbiota Differs between Hypercholesterolemic Subjects and Controls. Biomed Res Int. 2017;2017:8127814. doi: 10.1155/2017/8127814.

13. Morales C., Rojas G., Rebolledo C., et al. Characterization of microbial communities from gut microbiota of hypercholesterolemic and control subjects. Front Cell Infect Microbiol. 2022; 12: 943609. doi: 10.3389/fcimb.2022.943609.

14. Oinotkinova O. Sh., Nikonov E.L., Gioeva I.Z. The role of intestinal microbiota in the pathogenesis of dyslipidemia and associated metabolic disorders. Evidence-based gastroenterology. 2017;6(2):29 34. (In Russ.)@@ Ойноткинова О.Ш., Никонов Е.Л., Гиоева И.З. Роль микробиоты кишечника в патогенезе дислипидемии и ассоциированных метаболических нарушений. Доказательная гастроэнтерология. 2017;6(2):29 34.

15. Le Roy T., Lécuyer E., Chassaing B. et al. The intestinal microbiota regulates host cholesterol homeostasis. BMC Biol. 2019 Nov 27;17(1):94. doi: 10.1186/s12915-019-0715-8.

16. Xu Z., Jiang W., Huang W. et al. Gut microbiota in patients with obesity and metabolic disorders - a systematic review. Genes Nutr. 2022; 29;17(1):2. doi: 10.1186/s12263-021-00703-6.

17. Jin J., Cheng R., Ren Y. et al. Gut Microbiota in Patients with Overweight and Obesity with Dyslipidemia and its Responses to Long-term Orlistat and Ezetimibe Intervention: A Randomized Controlled Open-label Trial. Front. Pharmacol. 2021;12:732541. doi: 10.3389/fphar.2021.732541.

18. Cao K., Zhang K., Ma M. et al. Lactobacillus mediates the expression of NPC1L1, CYP7A1, and ABCG5 genes to regulate cholesterol. Food Sci Nutr. 2021;9(12):6882-6891. doi: 10.1002/fsn3.2600.